ASXL1 and myeloproliferative disorder: For MDS patients, mutations in CBL, IDH2, DNMT3A, TP53 or ASXL1, individually, are associated with shorter survival, with a 3‐year survival rate of only 27% for MDS/MPN patients characterized by having activating mutations of CBL.29, 30 Thus, novel treatment strategies that can be readily implemented in the clinic are needed.